|
2-3-11 Nihonbashi-Honcho, Chuo-ku Tokyo 103-8411, Japan Tel. +81-3-3244-3000 Fax +81-3-3244-3272 |
Type: Public
On the web:
http://www.astellas.com
Stars are formed by fusion processes, and so sometimes are companies. Astellas Pharma was born after Japanese pharmaceutical firms Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical Company merged in 2005, creating one of the largest pharmaceutical companies in Japan. Main products include gastritis treatment Gaster, hypertension therapy Micardis, urology treatment Vesicare, organ transplant immunosuppressant Prograf, and cholesterol drug Lipitor (sold in Japan via an agreement with Pfizer). Astellas' products (including those under development) include cardiovascular, central nervous system, oncology, diabetes, infectious disease, inflammation/immunology, gastroenterology, and urology therapies.
Key numbers for fiscal year ending March, 2008:
Sales: $9,794.9M
One year growth: 25.4%
Net income: $1,787.0M
Income growth: 60.4%
Officers:
Chairman: Toichi Takenaka
President, CEO, and Director: Masafumi Nogimori
Chief Strategy Officer and CFO: Yoshihiko Hatanaka
Competitors:
Daiichi Sankyo
Roche Holding
Takeda Pharmaceutical
